Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,558 questions in 115 reviews · Vascular
current versionsNo studies 346 · 22.2%Ungraded 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Prostanoids vs lumbar sympathectomy Mortality Clinical assessment · people with critical limb ischaemia due to non‐reconstructable peripheral arterial disease Lumbar sympathectomy versus prostanoids for critical limb ischaemia due to non‐reconstructable peripheral… (2018) · Cochrane | no estimate extracted | 1 study · 162 participants | Low |
Endovascular revascularisation vs no specific therapy Maximum walking distance · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | no estimate extracted | 3 studies · 125 participants | Moderate |
Endovascular revascularisation vs conservative therapy Pain‐free walking distance (long‐term) · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | no estimate extracted | 2 studies · 147 participants | Moderate |
Endovascular revascularisation vs conservative therapy Secondary invasive interventions · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | OR 1.4 [0.7, 2.8] | 4 studies · 395 participants | High |
Endovascular revascularisation vs conservative therapy Quality of life (disease‐specific) · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | no estimate extracted | 3 studies · 301 participants | High |
Endovascular revascularisation plus conservative therapy vs conservative therapy alone Maximum walking distance · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | no estimate extracted | 3 studies · 432 participants | Moderate |
Endovascular revascularisation plus conservative therapy vs conservative therapy alone Maximum walking distance (long‐term) · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | no estimate extracted | 1 study · 106 participants | Low |
Endovascular revascularisation plus conservative therapy vs conservative therapy alone Pain‐free walking distance · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | no estimate extracted | 2 studies · 305 participants | Moderate |
Endovascular revascularisation plus conservative therapy vs conservative therapy alone Pain‐free walking distance (long‐term) · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | no estimate extracted | NR | No studies |
Endovascular revascularisation plus conservative therapy vs conservative therapy alone Secondary invasive interventions · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | OR 0.27 [0.13, 0.55] | 3 studies · 457 participants | High |
Endovascular revascularisation plus conservative therapy vs conservative therapy alone Quality of life (disease‐specific) · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | no estimate extracted | 2 studies · 330 participants | Moderate |
Endovascular revascularisation vs no specific therapy Maximum walking distance (long‐term) · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | no estimate extracted | 2 studies · 103 participants | Low |
Endovascular revascularisation vs no specific therapy Pain‐free walking distance · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | no estimate extracted | 3 studies · 125 participants | Moderate |
Endovascular revascularisation vs no specific therapy Pain‐free walking distance (long‐term) · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | no estimate extracted | 2 studies · 103 participants | Low |
Endovascular revascularisation vs no specific therapy Secondary invasive interventions · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | OR 0.81 [0.12, 5.28] | 2 studies · 118 participants | Moderate |
Endovascular revascularisation vs no specific therapy Quality of life (disease‐specific) · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | no estimate extracted | NR | No studies |
Endovascular revascularisation vs conservative therapy Maximum walking distance · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | no estimate extracted | 5 studies · 345 participants | Moderate |
Endovascular revascularisation vs conservative therapy Maximum walking distance (long‐term) · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | no estimate extracted | 3 studies · 184 participants | Moderate |
Endovascular revascularisation vs conservative therapy Pain‐free walking distance · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | no estimate extracted | 5 studies · 345 participants | Moderate |
BM‐MNCs vs mPBSCs All‐cause mortality Assessed during in‐patient stay · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | no estimate extracted | 2 studies · 202 participants | Ungraded |
BM‐MNCs vs BM‐MSCs Reduction in rest pain: rest pain score · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | no estimate extracted | 1 study · 37 participants | Moderate |
BM‐MNCs vs BM‐MSCs Improvement in lower limb perfusion: ABI score · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | no estimate extracted | 1 study · 37 participants | Low |
BM‐MNCs vs BM‐MSCs Improvement in lower limb perfusion: TcO₂ reading in mmHg · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | no estimate extracted | 1 study · 37 participants | Low |
High cell dose vs low cell dose All‐cause mortality Assessed during in‐patient stay · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | no estimate extracted | 1 study · 16 participants | Ungraded |
High cell dose vs low cell dose Amputation rate Assessed during in‐patient stay (Losordo 2012) · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | RR 3.21 [0.87, 11.9] | 1 study · 16 participants | Very low |
High cell dose vs low cell dose Wound ulcer healing · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | no estimate extracted | NR | No studies |
High cell dose vs low cell dose Reduction in rest pain · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | no estimate extracted | NR | No studies |
High cell dose vs low cell dose Improvement in lower limb perfusion: ABI · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | no estimate extracted | NR | No studies |
High cell dose vs low cell dose Improvement in lower limb perfusion: TcO₂ · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | no estimate extracted | NR | No studies |
IM injection vs IA injection All‐cause mortality Assessed during in‐patient stay · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | no estimate extracted | 3 studies · 95 participants | Ungraded |
BM‐MNCs vs mPBSCs Amputation rate Assessed during in‐patient stay · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | RR 1.54 [0.45, 5.24] | 1 study · 150 participants | Low |
IM injection vs IA injection Amputation rate Assessed during in‐patient stay · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | RR 0.8 [0.54, 1.18] | 3 studies · 95 participants | Low |
IM injection vs IA injection Wound/ulcer healing: number of participants with healing ulcer · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | RR 1.13 [0.73, 1.76] | 1 study · 41 participants | Low |
IM injection vs IA injection Reduction in rest pain: number of participants with reduction in rest pain score · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | RR 1.22 [0.91, 1.64] | 1 study · 32 participants | Low |
IM injection vs IA injection Improvement in lower limb perfusion: number of participants with increased ABI · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | RR 0.93 [0.43, 2] | 1 study · 35 participants | Very low |
IM injection vs IA injection Improvement in lower limb perfusion: number of participants with improved TcO₂ reading · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | RR 1.22 [0.86, 1.72] | 2 studies · 62 participants | Very low |
BM‐MNCs vs mPBSCs Wound/ulcer healing: number of participants with healing ulcers Assessed during in‐patient stay · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | RR 0.89 [0.44, 1.83] | 1 study · 49 participants | Low |
BM‐MNCs vs mPBSCs Reduction in rest pain: number of participants with any reduction in rest pain score Assessed during in‐patient stay · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | RR 0.99 [0.93, 1.06] | 1 study · 104 participants | Moderate |
BM‐MNCs vs mPBSCs Improvement in lower limb perfusion: number of participants with increased ABI Assessed at 4 weeks · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | RR 1 [0.71, 1.4] | 1 study · 104 participants | Low |
BM‐MNCs vs mPBSCs Improvement in lower limb perfusion: TcO₂ reading in mmHg · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | no estimate extracted | 1 study · 150 participants | Low |
BM‐MNCs vs BM‐MSCs All‐cause mortality Assessed during in‐patient stay · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | no estimate extracted | 1 study · 37 participants | Ungraded |
BM‐MNCs vs BM‐MSCs Amputation rate Assessed during in‐patient stay · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | no estimate extracted | 1 study · 37 participants | Ungraded |
BM‐MNCs vs BM‐MSCs Wound/ulcer healing: number of participants with healing ulcers · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | RR 2 [1.02, 3.92] | 1 study · 22 participants | Moderate |
Gene therapy vs no gene therapy control Amputation‐free survival · peripheral arterial disease Gene therapy for peripheral arterial disease (2018) · Cochrane | OR 1.68 [0.75, 3.76] | 4 studies · 756 participants | Moderate |
Gene therapy vs no gene therapy control Ulcer healing · peripheral arterial disease Gene therapy for peripheral arterial disease (2018) · Cochrane | OR 2.16 [1.02, 4.59] | 5 studies · 238 participants | Low |
Gene therapy vs no gene therapy control Quality of life · peripheral arterial disease Gene therapy for peripheral arterial disease (2018) · Cochrane | no estimate extracted | 6 studies · 699 participants | Very low |
Gene therapy vs no gene therapy control Amputation (above‐ankle amputation of the index limb) · peripheral arterial disease Gene therapy for peripheral arterial disease (2018) · Cochrane | OR 1.06 [0.77, 1.46] | 11 studies · 1336 participants | Moderate |
Gene therapy vs no gene therapy control All‐cause mortality · peripheral arterial disease Gene therapy for peripheral arterial disease (2018) · Cochrane | OR 0.93 [0.66, 1.31] | 12 studies · 1685 participants | Moderate |
Gene therapy vs no gene therapy control ABI ‐ change from baseline · peripheral arterial disease Gene therapy for peripheral arterial disease (2018) · Cochrane | no estimate extracted | 1 study · 125 participants | Low |
Gene therapy vs no gene therapy control Pain symptom scores (VAS) ‐ change from baseline · peripheral arterial disease Gene therapy for peripheral arterial disease (2018) · Cochrane | no estimate extracted | 2 studies · 152 participants | Very low |